Mission Produce, Inc. reported its fourth-quarter fiscal year 2024 earnings, revealing a total revenue of $354.4 million, a 37% increase year-over-year, and net income of $17.3 million, or $0.24 per diluted share, compared to $4.0 million, or $0.06 per diluted share, for the same period last year. The adjusted earnings per share (EPS) for the quarter was $0.28, surpassing estimates of $0.22. The company's strong performance was attributed to high avocado prices, which contributed to a 160% profit surge. In related news, Humacyte, Inc. received FDA approval for SYMVESS, a first-in-class bioengineered vessel for treating extremity vascular trauma. The approval has led to a surge in Humacyte's stock, which rose by 61% in pre-market trading. SYMVESS is designed as an off-the-shelf alternative to autologous vein grafts, aimed at improving outcomes in limb-threatening vascular trauma. The FDA emphasized that this acellular tissue engineered vessel is intended for use when urgent revascularization is necessary and traditional grafts are not feasible.